Ligand (Group)

https://www.ligand.com

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono-and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly. *

	Start	1999-03-08 existent
	Industry	biopharmaceutical

	Region	San Diego, CA
	Country	United States (USA)
	Street	11119 North Torrey Pines Road Suite 200
	City	92037 La Jolla, CA
	Tel	+1-858-550-7500
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	12,894,000 (revenue, total, consolidated (2007) 2007-12-31)
	Profit	281,688,000 (2007-12-31)
	Cash	94,408,000 (2007-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10